Viraday
Emtricitabine · Tenofovir Disoproxil · Efavirenz
Designed to support retroviral load management to manage CD4 cell levels and alleviate risk of opportunistic infections.
- Category
- HIV Management
- Active ingredients
- Emtricitabine · Tenofovir Disoproxil · Efavirenz
- Route
- Oral use
- Form
- Tablet
- Strengths
- 1.1gm
Prescription and consultation requirements for Viraday vary by destination and are determined by the fulfilment partner.
Viraday details
- Alternative names
- emtricitabine, tenofovir, efavirenz
- Therapeutic class
- Nucleoside Analog and Non-Nucleoside Reverse Transcriptase Inhibitor Combination
- Pharmacological class
- Antiretroviral Combination
- Minor side effects
- dizziness; headache; insomnia
- Moderate side effects
- vivid dreams; rash; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Cipla Ltd
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Rifampin; Simvastatin; St. John's Wort
- Age restrictions
- Approved for adults weighing over forty kilograms.
Contraindications
severe renal impairment; concurrent highly CYP3A4-dependent therapies; hepatic failure
Serious side effects
lactic acidosis, requires immediate medical attention; severe hepatotoxicity, requires immediate medical attention; suicidal ideation, requires immediate medical attention
Patient summary
designed to support retroviral load management to manage CD4 cell levels and alleviate risk of opportunistic infections.
Mechanism of action
Combines emtricitabine and tenofovir to terminate the viral DNA chain with efavirenz to inhibit reverse transcriptase non-competitively.
Pregnancy and breastfeeding
TGA Category D: Avoid in first trimester. Discontinue breastfeeding to prevent transmission.